Article

LASIK may be OK for some autoimmune patients

Although the FDA considers autoimmune diseases a contraindication for LASIK regardless of disease severity, a retrospective study suggests that the surgery may be appropriate in patients with well-controlled or inactive disease, said Ronald J. Smith, MD, MPH, of Beverly Hills.

Although the FDA considers autoimmune diseases a contraindication for LASIK regardless of disease severity, a retrospective study suggests that the surgery may be appropriate in patients with well-controlled or inactive disease, said Ronald J. Smith, MD, MPH, of Beverly Hills.

There have been no prospective clinical trials that have included patients with autoimmune diseases, although one case report cited a patient with lupus who developed corneal melt following PRK. Conflicting evidence has emerged from reports of cataract surgery on patients with autoimmune disease. However, this evidence should not necessarily be generalized to all patients with autoimmune diseases who are considering refractive surgery, Dr. Smith said.

He and colleague Robert Maloney, MD, of Los Angeles, conducted a retrospective analysis of patients undergoing LASIK at the Maloney Vision Institute, reviewing records for a history of any autoimmune disease. They identified 49 eyes of 26 patients with an autoimmune disease, most commonly lupus or rheumatoid arthritis. In all cases, the disease was inactive or the patients were stable on medication.

"None of our patients developed any of the corneal scleral complications," Dr. Smith said. "There were no corneal melts, no stage IV or central toxic keratopathy, no persistent epithelial defects, and no scleral melts."

These results were similar to the findings of several other recent studies.

"LASIK may be reasonable in patients with well-controlled or inactive autoimmune disease who are otherwise good candidates for LASIK," Dr. Smith said. He added that proper informed consent must be obtained.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.